Bhumika Shah, MD

  • 7Articles
  • 50.5KReads1
  • 2020–2024Active
  • 20Collaborators
  • 31Citations2

About

Bhumika Shah, MD, is affiliated with the Department of Psychiatry and Behavioral Science at the University of Louisville, Kentucky. Shah has published extensively from 2020 to 2024 on topics including psychopharmacology, depression, addiction, complementary and alternative medicine, and COVID-19. The author’s work addresses drug interactions between psychotropic medications and treatments for infections such as Mpox and COVID-19, as well as clinical perspectives on opioid use disorder and treatment-resistant depression. Shah frequently collaborates with colleagues including Zeeshan Mansuri and Taranjeet Jolly.

Publications

PCC
Drug Interactions Between Psychotropic Medications and Mpox Treatment
Letter to the Editor

Drug Interactions Between Psychotropic Medications and Mpox Treatment

February 15, 2024

The authors review pharmacologic interactions of Mpox treatments with psychotropic medications and antidepressants, antipsychotics, mood stabilizers, and sedatives.
, , , et al
PCC
Intravenous Ketamine vs Intranasal Esketamine for TRD
Letter to the Editor

Intravenous Ketamine vs Intranasal Esketamine for TRD

February 13, 2024

Dr Mansuri and colleagues compare the pros and cons of IV ketamine and intranasal esketamine for treatment-resistant depression.
, , , et al
PCC
Impact of Paternal Depression on Children
Systematic Review

Impact of Paternal Depression on Children

February 7, 2023

An association exists between paternal mental health and depressive symptoms and neurodevelopmental disorders in infants and children.
, , , et al
PCC
Letter to the Editor

Interactions With IL-6 Inhibitors and Agents for Opioid Use: Drs Mansuri and Colleagues Reply

February 18, 2021

In this letter to the editor, the authors reply to Kow and Hasan.
, , , et al
PCC
Commentary

Opioid Use Disorder Treatment and Interaction With COVID-19 Medication

July 2, 2020

In this commentary, the authors discuss the potential interactions of opioid use disorder treatments with novel COVID-19 medications.
, , , et al
PCC
Commentary

Interactions of Ritonavir/Lopinavir With Psychiatric Medications: A COVID-19 Perspective

June 18, 2020

In this commentary, the authors discuss the potential interactions of ritonavir/lopinavir with psychiatric medications in the context of COVID-19.
, , , et al
PCC
Commentary

Potential Interactions of Remdesivir With Psychotropics

May 28, 2020

The FDA has approved remdesivir for severe COVID-19 in children and adults. This commentary reviews potential interactions of remdesivir with psychotropic medications.
, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe